

Volumetric brain differences in clinical depression in association with anxiety: a systematic review with meta-analysis

Daniela A. Espinoza Oyarce, MNeurosci; Marnie E. Shaw, PhD;
Khawlah Alateeq, MMagResonTech; Nicolas Cherbuin, PhD

Published online on July 29, 2020; subject to revision

Background: Structural differences associated with depression have not been confirmed in brain regions apart from the hippocampus. Comorbid anxiety has been inconsistently assessed, and may explain discrepancies in previous findings. We investigated the link between depression, comorbid anxiety and brain structure. **Methods:** We followed Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines (PROSPERO CRD42018089286). We searched the Cochrane Library, MEDLINE, PsycInfo, PubMed and Scopus, from database inception to Sept. 13, 2018, for MRI case-control studies that reported brain volumes in healthy adults and adults with clinical depression. We summarized mean volumetric differences using meta-analyses, and we assessed demographics, depression factors and segmentation procedure as moderators using meta-regressions. **Results:** We included 112 studies in the meta-analyses, assessing 4911 healthy participants and 5934 participants with depression (mean age 49.8 yr, 68.2% female). Volume effects were greater in late-onset depression and in multiple episodes of depression. Adults with depression and no comorbidity showed significantly lower volumes in the putamen, pallidum and thalamus, as well as significantly lower grey matter volume and intracranial volume; the largest effects were in the hippocampus (6.8%, $p < 0.001$). Adults with depression and comorbid anxiety showed significantly higher volumes in the amygdala (3.6%, $p < 0.001$). Comorbid anxiety lowered depression effects by 3% on average. Sex moderated reductions in intracranial volume. **Limitations:** High heterogeneity in hippocampus effects could not be accounted for by any moderator. Data on symptom severity and medication were sparse, but other factors likely made significant contributions. **Conclusion:** Depression-related differences in brain structure were modulated by comorbid anxiety, chronicity of symptoms and onset of illness. Early diagnosis of anxiety symptomatology will prove crucial to ensuring effective, tailored treatments for improving long-term mental health and mitigating cognitive problems, given the effects in the hippocampus.

Introduction

Globally, depression is the most prevalent and disabling psychiatric disorder.^{1,2} It affects approximately 4.4% of the population, is the leading reason for disease burden² and is the fourth leading cause of disability.^{1,3} The burden and prevalence of depression have increased steadily as a result of population growth and aging^{1,2}; given that this trend is expected to continue, it is critical that we better understand the neurobiological determinants and progression of depression to improve prevention and management. Although a vast literature is available investigating the structural brain changes associated with depression, no consensus has been established for direction or magnitude. Indeed, even in the hippocampus

— which has consistently been found to be substantially smaller in people with depression^{4–12} — the magnitude of the effect is variable and appears to be dependent on age, number of depressive episodes and illness duration,^{7,12} remission status^{5,10} and laterality.^{6–8} Furthermore, increasing evidence that some pharmacological treatments may be protective against volume loss^{11,13–16} add further variability to these findings.

Depression is not a uniform disorder, and comorbidity with other psychiatric disorders (most notably anxiety^{2,17}) intrinsically imposes variability on the research. Anxiety is the second most prevalent psychiatric disorder,^{1,2} and depression comorbid with anxiety has been associated with poorer health outcomes, including more severe symptoms and higher levels of suicidal ideation.¹⁸ Given comorbidity rates

Correspondence to: D.A. Espinoza Oyarce, Centre for Research on Ageing, Health and Wellbeing, The Australian National University, Florey Building 54, Mills Road, Acton 2601, Canberra, Australia; danielaandrea.espinozaoyarce@anu.edu.au

Submitted Sep. 17, 2019; Revised Feb. 7, 2020; Accepted Feb. 27, 2020

DOI: 10.1503/jpn.190156

as high as 50%,^{17,18} it is vital to exclude — or at least account for — anxiety disorders when investigating structural brain changes associated with depression. Previous reviews have focused largely on the effects of age and sex — and on variables such as symptom severity, number of episodes and medication^{4–8,10,12,19–21} — to explain some of the variability in brain volume. Only 2 of these reviews^{5,12} addressed anxiety comorbidity, and although they reported no moderating effects, a voxel-based morphometry review²² contradicted these results.

The present study aimed to provide a comprehensive summary of the literature investigating structural brain changes with depression, considering global and regional volumetric measures using MRI and a specific type of depressive disorder (major depressive disorder) and its different subclassifications to provide a more targeted approach. Crucially and unlike previous reviews, the present study also comprehensively investigated the effect of comorbidity in an effort to distinguish the contributions of depression from those of anxiety. It provides precise volumetric difference estimates not currently available in the literature.

Methods

This systematic review with meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines²³ and was prospectively registered in the PROSPERO database (CRD42018089286).

Search strategy

We searched the Cochrane Library, MEDLINE, PsycInfo, PubMed and Scopus from database inception to Sept. 13, 2018, to identify studies reporting on depression, anxiety and brain measures obtained by MRI in humans. We used the following search string: (brain or grey matter or white matter or cortex or lobe or frontal or parietal or temporal or occipital or cingulate or CC or hippocamp* or amygdala* or hypothalamus or basal ganglia) and (atrophy or change or difference or volume or volumetr*) and (MRI or magnetic resonance imag* or neuroimaging) and (depress* or major depressive disorder or MDD or suicide* or low mood or sad or sadness or anx* or neurotic* or stress or distress or generalized anxiety disorder or GAD or social anxiety). Whenever possible, we used database filters to exclude nonhuman studies and studies not published in English.

Screening

Duplicate records were removed, and a single author (D.E.O.) excluded irrelevant entries by title screening. The abstracts of the remaining records were then double-screened by 2 other authors, and any discrepancies were resolved by consensus. Finally, following the same method, we retrieved full-text and supplemental material of the selected studies for screening against the inclusion and exclusion criteria. We also examined the bibliographies of retrieved studies and previous reviews to identify any additional studies for inclusion.

Inclusion and exclusion criteria

Studies were included based on the following criteria: was an empirical study; examined global, lobar or regional brain volumes in adult human samples; measurement of brain volume was derived from structural MRI data using manual or automated segmentation; and included at least 1 group of cognitively healthy participants free of psychiatric illness contrasted with participants who were clinically diagnosed with depression (based on the *Diagnostic and Statistical Manual of Mental Disorders* or the *International Classification of Diseases*), with or without comorbid anxiety disorders.

Studies were excluded based on the following criteria: were randomized controlled trials; reported only postmortem MRI data; did not report brain volumes; focused exclusively on samples with behavioural problems, substance abuse, systemic illness or major structural abnormalities (i.e., stroke, brain injury); involved whole samples with mental illness other than depression or depression comorbid with anxiety disorders; did not provide sex or age of the sample, or included participants younger than 18 years; had samples of fewer than 40 participants in total; or were published in a language other than English.

Data extraction

To avoid transcription errors, data were double-extracted by 2 authors, and any discrepancies were resolved by consensus. We extracted the mean and standard deviation (SD) of raw volumes for healthy controls and participants with depression. We converted other measures of variance to SD according to published methods,²⁴ and the unit of measurement was set to millilitres. Further details on extracted variables can be found in Appendix 1, available at jpn.ca/190156-a1. Whenever essential data were not reported, they were requested directly from authors. If data could not be obtained, studies were excluded from statistical analyses. Only cross-sectional data were used in this review.

During data extraction, we identified studies reporting on the same or overlapping samples, on homogeneous populations or on particular depression subgroups. Subgroup classifications included current or remitted depression; a subtype of depression (melancholic, psychotic or atypical); first or multiple episodes of depression; age of onset of depression (pediatric, adult, early or late); family history of depression; intake of antidepressants; treatment resistance; comorbidity with anxiety disorders; suicide attempt or ideation; and physical or sexual abuse. Heterogeneous samples and samples that could not be included in the above categories because of a lack of information were merged into a single separate group to account for some variability (mixed group; Appendix 1).

Primary outcome measure

The primary outcome measure was the mean difference between brain volumes in healthy controls and participants with depression. Thus, positive outcome measures corresponded to higher volumes in healthy controls, and negative

outcome measures corresponded to higher volumes in participants with depression. We investigated total brain volume, grey matter volume, white matter volume and intracranial volume using mean difference in total volume. We investigated subcortical structures using mean differences in total, right and left volumes. When total volumes were not reported, we derived mean and SD volumes from the right and left volumes (Appendix 1).

Statistical analysis

We used R version 3.3.1²⁵ for Windows to conduct statistical analyses. We conducted meta-analyses and meta-regressions using the metafor package version 1.9–9.²⁶

Meta-analyses

We conducted all meta-analyses using a random-effects model with a restricted maximum likelihood estimator, where the summary outcome was the mean of the distribution of volume differences adjusted for sample size.²⁷ We examined heterogeneity using the Cochran *Q* statistic, which provides the ratio of variation within studies (significance $p \leq 0.05$),²⁷ and the *I*² statistic, which provides a measure of inconsistency across observed volume differences (25%, 50% and 75% corresponding to low, moderate and high, respectively^{27,28}). Finally, we examined the spread of observed volume differences using the τ^2 statistic, which shows the variance of the summary outcome.²⁷

We conducted meta-analyses focused on different brain areas or clinical subgroups provided that a minimum of 3 studies were available. Furthermore, we examined the effect of comorbidity between depression and anxiety disorders where possible with studies that excluded or included clinically diagnosed anxiety, either by axis I or explicit comorbidity exclusion (Appendix 1). Management of duplicate samples was specific to brain region and type of analysis. Whenever we identified duplicates, we included the study with the largest sample size and excluded all others from the specific analysis. If the sample size was identical, we included the most recent study and all others excluded from the specific analysis. A $p \leq 0.05$ was considered significant.

Meta-regressions

We investigated the moderating effects of age and sex on mean volumetric differences in total brain volume, hippocampal volume and intracranial volume given the greater number of included studies.²⁷ In line with this principle, we further investigated segmentation procedure, depressive symptoms and medication status for hippocampal volume. We centred age at 30 years to provide a meaningful estimate of volumetric differences. We investigated sex first as percentage of female participants, and then as the difference in the percentage of female participants among healthy controls and participants with depression because of high variability in some studies. We investigated segmentation by contrasting manual and automated segmentation. We investigated depressive symptoms with the 17-item Hamilton Depression Rating Scale, given the greater number of studies reporting

this measure. Finally, we investigated medication status as the percentage of participants taking antidepressants (Appendix 1). We further investigated the effect of age in meta-analyses stratified by participants younger than 55 years and participants 55 years and older. We found no significant differences between these groups (data not shown).

Sensitivity analyses

Because the summary outcome is dependent on the type of samples being contrasted, we conducted sensitivity analyses to investigate the influence of studies reporting measures for participants with depression in mixed groups and homogeneous groups. We found no significant differences (Appendix 1, Tables S6 and S7). Finally, we used the leave-one-out method to determine whether individual studies contributed disproportionately to any inhomogeneity of effects.

Quality assessment

Two authors independently assessed the quality of the studies based on a modified version of the Newcastle–Ottawa Scale (Appendix 1);²⁹ discrepancies were resolved by consensus.

Bias assessment

We assessed publication bias graphically using funnel plots. We used the Egger regression test^{26,30,31} with standard error as a predictor to provide objective interpretation. We used the trim-and-fill method^{32,33} to estimate the effect of any extreme studies missing from the meta-analyses.

Results

Literature search

Online searches identified 9229 unique references, and manual searches identified a further 19 studies, leaving 9248 studies for screening after duplicates were removed (Fig. 1). Following exclusion of irrelevant references and assessment against inclusion and exclusion criteria, 327 studies were included in the review. Of these, 31 population studies and 75 voxel-based morphometry studies were further excluded. After accounting for duplicate samples and structures not included because of insufficient numbers of studies (Appendix 1), 112 studies were included in meta-analyses with a total of 10845 participants (4911 healthy controls and 5934 participants with depression; mean age 49.8 yr, 68.2% female). A detailed description of these studies is provided in Appendix 1, Table S2. The average Newcastle–Ottawa Scale rating was 6.9, with a minimum score of 4.5 in 3 studies (Appendix 1, Table S3). The Newcastle–Ottawa Scale scores had no moderating effects (Appendix 1).

Main effect of depression

We investigated 11 regions, given minimum requirements: 4 global and 7 subcortical structures. A summary of volumetric differences between healthy controls and participants with depression in each region is provided

in Figure 2 (left), showing greater effects in subcortical structures. We found no significant volume differences in the total brain (31 studies), amygdala (total volume: 16 studies; right/left: 14 studies), caudate (total volume: 13 studies; right/left: 9 studies), pallidum (total volume: 9 studies, right/left: 7 studies), accumbens (4 studies) or

white matter (10 studies; Table 1 and Appendix 1, Table S4 for detailed demographics).

Grey matter volume

Fifteen studies reported grey matter volume differences ($n = 1788$, age = 40.8 yr, 57.3% female).^{17,34-47} Significant differences




Fig. 1: PRISMA flowchart of included studies. VBM = voxel-based morphometry.

represented 0.9% ($z = 2.274, p = 0.023$) lower grey matter volume in participants with depression (Table 1, Fig. 3A and Appendix 1, Fig. S3).

Hippocampus

Fifty-one studies reported total hippocampal volume differences ($n = 4723$, age 48.6 yr, 63.2% female)^{21,40,44,48-95} Significant differences represented 3.2% ($z = 5.026, p < 0.001$) lower total hippocampal volume in participants with depression. We also found significant differences in 3 subgroups indicating that, compared with healthy controls, participants with depression in mixed groups had 4.3% ($z = 4.487, p < 0.001$) lower total hippocampal volume, participants with late-onset depression had 5.9% ($z = 3.464, p < 0.001$) lower total hippocampal volume and participants with depression with multiple episodes had 5.9% ($z = 3.503, p < 0.001$) lower total hippocampal volume. All significant results showed significant heterogeneity (Table 1, Fig. 4 and Appendix 1, Fig. S5).

Forty-three studies reported right and left hippocampal volume differences ($n = 4291$, age 48.8 yr, 63.2% female)^{40,44,50-58,60-62,64,66,68-75,77-79,81-91,93-97} Significant differences

represented 3.6% ($z = 4.963, p < 0.001$) lower right and 3.4% ($z = 4.561, p < 0.001$) lower left hippocampal volume in participants with depression. We also found significant differences in 3 subgroups indicating that, compared with healthy controls, participants with depression in mixed groups had 4.4% ($z = 4.347, p < 0.001$) lower right and 4.4% ($z = 4.227, p < 0.001$) lower left hippocampal volume, participants with late-onset depression had 6.8% ($z = 3.360, p < 0.001$) lower right and 6.2% ($z = 3.622, p < 0.001$) lower left hippocampal volume and participants with depression with multiple episodes had 6.5% ($z = 6.111, p < 0.001$) lower right and 4.6% ($z = 2.244, p = 0.025$) lower left hippocampal volume. We found significant differences in participants with early-onset depression only in right hippocampal volume, representing 4.3% ($z = 2.186, p = 0.029$) lower volume. With few exceptions, all significant results showed significant heterogeneity (Table 1, Fig. 5, Fig. 6 and Appendix 1, Fig. S7 and S9).

Putamen

Thirteen studies reported total putamen volume differences ($n = 1693$, age 46.1 yr, 62.3% female)^{60,63,71,75,83,88,94,98-103} Significant differences represented 2.3% ($z = 2.823, p = 0.005$) lower




Fig. 2: Volumetric differences in depression. Percent difference between volumes of healthy controls and participants with depression per brain region in depression (left, grey), and the effects without comorbid anxiety (middle, black) and with comorbid anxiety (right, light grey). Positive values represent greater volumes in healthy controls, and negative values represent greater volume in participants with depression. Error bars represent 95% confidence interval. *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$. GMV = grey matter volume; ICV = intracranial volume; LAV = left amygdala volume; LCV = left caudate volume; LHcV = left hippocampus volume; LPaV = left pallidum volume; LPuV = left putamen volume; LTV = left thalamus volume; RAV = right amygdala volume; RCV = right caudate volume; RHcV = right hippocampus volume; RPaV = right pallidum volume; RPuV = right putamen volume; RTV = right thalamus volume; TAcV = total accumbens volume; TAV = total amygdala volume; TBV = total brain volume; TCV = total caudate volume; THcV = total hippocampus volume; TPaV = total pallidum volume; TPuV = total putamen volume; TTV = total thalamus volume; WMV = white matter volume.

Table 1: Meta-analyses per brain region (part 1 of 3)

Region	Analysis	Studies, n	k	n			Depression	Mean volume difference ± SE (95% CI), mL	Meta-analysis results		
				Total	Control	Depression			p value	τ ²	Q p
Total brain	DEP	27	37	2618	1123	1495	-1.506 ± 4.127 (-9.595 to 6.583)	0.72	0.000	0.28	0.00
	DEP-Mix	12	13	1233	524	709	8.375 ± 6.116 (-3.612 to 20.361)	0.17	0.000	0.18	0.00
	DEP-EO	6	6	370	208	162	2.201 ± 11.192 (-19.734 to 24.136)	0.84	0.000	0.85	0.00
	DEP-LO	7	7	413	220	193	16.391 ± 12.855 (-8.805 to 41.587)	0.20	688.646	< 0.001*	71.95*
	DEP-Rem	4	4	261	151	110	7.234 ± 16.222 (-24.561 to 39.029)	0.66	0.000	0.93	0.00
	DEP-Cur	4	4	617	295	322	-7.031 ± 10.479 (-27.570 to 13.508)	0.50	0.000	0.94	0.00
	DEP	15	19	1788	823	965	5.541 ± 2.437 (0.765 to 10.318)	0.023*	0.000	0.28	0.00
Grey matter	DEP-Mix	4	4	512	261	251	1.999 ± 5.425 (-8.633 to 12.632)	0.71	0.000	0.61	0.00
	DEP-FE	5	5	415	224	191	6.125 ± 4.440 (-2.578 to 14.827)	0.17	0.000	0.55	0.00
	DEP-TR	3	3	421	175	246	10.666 ± 8.021 (-5.054 to 26.387)	0.18	93.016	0.14	47.89
	DEP	10	12	1245	508	737	-2.351 ± 3.377 (-8.969 to 4.267)	0.49	12.782	0.22	9.34
	DEP-Mix	3	3	460	239	221	-0.346 ± 5.599 (-11.320 to 10.628)	0.95	0.000	0.69	0.00
White matter	DEP-FE	3	3	226	108	118	6.645 ± 9.677 (-12.323 to 25.612)	0.49	75.471	0.24	25.98
	DEP	42	59	3775	1728	2047	5.806 ± 4.516 (-3.045 to 14.658)	0.20	220.756	0.07	21.38
	DEP-Mix	25	25	2235	1080	1155	11.731 ± 5.838 (0.288 to 23.173)	0.045*	121.417	0.28	15.50
	DEP-EO	5	5	434	274	160	5.162 ± 18.859 (-31.800 to 42.125)	0.78	839.154	0.11	48.09
	DEP-LO	3	3	198	110	88	13.652 ± 18.797 (-23.189 to 50.492)	0.47	0.000	0.54	0.00
Intracranial	DEP-FE	4	4	337	231	106	8.328 ± 18.012 (-26.975 to 43.631)	0.64	327.309	0.27	23.99
	DEP-ME	4	4	493	320	173	22.036 ± 20.536 (-18.214 to 62.286)	0.28	919.847	0.06	56.87*
	DEP-noMed	6	6	302	176	126	-18.519 ± 16.384 (-50.630 to 13.592)	0.26	0.000	0.67	0.00
	DEP-Med	4	4	192	137	55	-0.831 ± 23.732 (-47.345 to 45.683)	0.97	0.000	0.98	0.00
	DEP-TR	3	3	366	138	228	-0.749 ± 18.685 (-37.371 to 35.874)	0.97	0.000	0.99	0.00
	DEP-Rem	3	5	266	140	126	-14.587 ± 14.135 (-42.291 to 13.116)	0.30	0.000	0.31	0.00
	DEP-Cur	5	5	386	210	176	-6.795 ± 19.324 (-44.670 to 31.079)	0.73	627.956	0.13	34.19
	DEP	42	61	3879	1737	2142	0.202 ± 0.040 (0.123 to 0.281)	< 0.001*	0.072	< 0.001*	86.58*
	DEP-Mix	24	26	1826	881	945	0.267 ± 0.059 (0.150 to 0.383)	< 0.001*	0.071	< 0.001*	83.25*
	DEP-EO	4	4	344	197	147	0.153 ± 0.096 (-0.035 to 0.340)	0.11	0.019	0.09	53.55*
Total hippocampus	DEP-LO	7	7	488	266	222	0.347 ± 0.100 (0.151 to 0.543)	< 0.001*	0.049	< 0.001*	77.86*
	DEP-FE	7	8	497	310	187	0.105 ± 0.108 (-0.106 to 0.316)	0.33	0.064	< 0.001*	73.46*
	DEP-ME	4	5	500	316	184	0.320 ± 0.091 (0.141 to 0.499)	< 0.001*	0.024	0.011*	68.43*
	DEP-noMed	3	3	138	74	64	0.121 ± 0.168 (-0.209 to 0.451)	0.47	0.049	0.08	59.43*
	DEP-TR	3	3	352	130	222	0.546 ± 0.284 (-0.011 to 1.103)	0.05	0.207	< 0.001*	96.82*
	DEP-Rem	6	8	603	364	239	-0.022 ± 0.050 (-0.121 to 0.076)	0.66	0.000	0.84	0.00
	DEP-Cur	7	7	967	464	503	0.108 ± 0.078 (-0.044 to 0.260)	0.16	0.025	0.010*	64.83*

Table 1: Meta-analyses per brain region (part 2 of 3)

Region	Analysis	Studies, n	k	Total	n		Depression	Mean volume difference ± SE (95% CI), mL	Meta-analysis results			
					Control	Depression			p value	τ ²	Q p	I ² , %
Right hippocampus	DEP	34	50	3447	1544	1903	0.114 ± 0.023 (0.069 to 0.159)	< 0.001*	0.017	< 0.001*	76.61*	
	DEP-Mix	20	21	1594	783	811	0.137 ± 0.031 (0.075 to 0.198)	< 0.001*	0.013	< 0.001*	68.44*	
	DEP-EO	4	4	344	197	147	0.118 ± 0.054 (0.012 to 0.223)	0.03*	0.005	0.13	44.34	
	DEP-LO	6	6	451	244	207	0.204 ± 0.061 (0.085 to 0.323)	< 0.001*	0.011	0.047*	54.43*	
	DEP-FE	7	8	497	310	187	0.047 ± 0.062 (-0.074 to 0.168)	0.44	0.017	0.012*	61.02*	
	DEP-ME	4	5	500	316	184	0.183 ± 0.030 (0.125 to 0.242)	< 0.001*	0.000	0.21	5.69	
	DEP-Rem	6	8	603	364	239	-0.020 ± 0.033 (-0.085 to 0.046)	0.56	0.000	0.93	0.00	
	DEP-Cur	5	5	847	409	438	0.052 ± 0.047 (-0.040 to 0.144)	0.27	0.004	0.14	40.92	
Left hippocampus	DEP	34	50	3447	1544	1903	0.105 ± 0.023 (0.060 to 0.150)	< 0.001*	0.017	< 0.001*	77.01*	
	DEP-Mix	20	21	1594	783	811	0.133 ± 0.031 (0.071 to 0.194)	< 0.001*	0.013	< 0.001*	67.97*	
	DEP-EO	4	4	344	197	147	0.051 ± 0.041 (-0.030 to 0.132)	0.21	0.001	0.31	14.68	
	DEP-LO	6	6	451	244	207	0.176 ± 0.049 (0.081 to 0.271)	< 0.001*	0.005	0.18	34.90	
	DEP-FE	7	8	497	310	187	0.068 ± 0.052 (-0.033 to 0.169)	0.19	0.011	0.040*	52.77*	
	DEP-ME	4	5	500	316	184	0.121 ± 0.054 (0.015 to 0.227)	0.025*	0.008	0.023*	62.41*	
	DEP-Rem	6	8	603	364	239	-0.001 ± 0.034 (-0.067 to 0.065)	0.98	0.000	0.79	0.00	
	DEP-Cur	5	5	847	409	438	0.042 ± 0.048 (-0.052 to 0.136)	0.38	0.005	0.13	46.31	
Total amygdala	DEP	15	25	1181	463	718	0.091 ± 0.061 (-0.029 to 0.211)	0.14	0.081	< 0.001*	90.25*	
	DEP-Mix	6	6	362	167	195	0.018 ± 0.087 (-0.153 to 0.188)	0.20	0.035	0.001*	78.81*	
	DEP-FE	3	3	177	91	86	-0.146 ± 0.182 (-0.503 to 0.211)	0.42	0.087	< 0.001*	89.00*	
	DEP-Rem	5	7	274	138	136	-0.035 ± 0.049 (-0.131 to 0.060)	0.47	0.007	0.07	42.17	
	DEP-Cur	4	4	193	103	90	-0.025 ± 0.092 (-0.204 to 0.155)	0.79	0.017	0.12	50.56*	
	DEP	13	23	1071	427	644	0.044 ± 0.029 (-0.014 to 0.101)	0.14	0.014	< 0.001*	77.75*	
	DEP-Mix	5	5	301	151	150	0.001 ± 0.035 (-0.067 to 0.069)	0.98	0.002	0.19	31.11	
	DEP-FE	3	3	177	91	86	-0.074 ± 0.087 (-0.244 to 0.096)	0.40	0.016	0.017*	73.80*	
Left amygdala	DEP	13	23	1071	427	644	0.026 ± 0.035 (-0.042 to 0.095)	0.45	0.022	< 0.001*	84.24*	
	DEP-Mix	5	5	301	151	150	-0.013 ± 0.053 (-0.117 to 0.090)	0.80	0.010	0.008*	72.34*	
	DEP-FE	3	3	177	91	86	-0.064 ± 0.099 (-0.257 to 0.130)	0.52	0.024	0.001*	82.32*	
	DEP-Rem	5	7	274	138	136	-0.027 ± 0.033 (-0.091 to 0.038)	0.42	0.003	0.12	36.44	
	DEP-Cur	3	3	144	83	61	-0.059 ± 0.037 (-0.132 to 0.013)	0.11	0.000	0.88	0.00	
	DEP	13	20	1693	716	977	0.212 ± 0.075 (0.065 to 0.359)	0.005*	0.059	< 0.001*	59.70*	
	DEP-Mix	8	8	856	375	481	0.203 ± 0.074 (0.058 to 0.348)	0.006*	0.000	0.65	0.00	
	DEP	9	15	1248	518	730	0.088 ± 0.044 (0.002 to 0.175)	0.046*	0.010	0.09	37.43	
Right putamen	DEP	5	5	524	224	300	0.094 ± 0.062 (-0.028 to 0.215)	0.13	0.000	0.86	0.00	
	DEP-Mix	9	15	1248	518	730	0.081 ± 0.047 (-0.010 to 0.173)	0.08	0.011	0.07	39.47	
	DEP	5	5	524	224	300	0.071 ± 0.059 (-0.044 to 0.187)	0.23	0.000	0.73	0.00	
	DEP-Mix	13	20	1686	697	989	0.031 ± 0.059 (-0.085 to 0.147)	0.60	0.031	0.005*	51.88*	
	DEP	8	8	849	356	493	0.140 ± 0.086 (-0.028 to 0.308)	0.10	0.016	0.24	28.16	

Table 1: Meta-analyses per brain region (part 3 of 3)

Region	Analysis	Studies, <i>n</i>	<i>k</i>	<i>n</i>			Meta-analysis results				
				Total	Control	Depression	Mean volume difference ± SE (95% CI), mL	<i>p</i> value	τ^2	<i>Q</i> , <i>p</i>	<i>I</i> ² , %
Right caudate	DEP	9	15	1241	499	742	0.017 ± 0.036 (-0.053 to 0.086)	0.64	0.006	0.11	33.31
	DEP-Mix	5	5	517	205	312	0.060 ± 0.051 (-0.039 to 0.160)	0.23	0.000	0.38	1.71
Left caudate	DEP	9	15	1241	499	742	0.021 ± 0.032 (-0.041 to 0.083)	0.51	0.004	0.13	25.39
	DEP-Mix	5	5	517	205	312	0.080 ± 0.053 (-0.024 to 0.184)	0.13	0.003	0.23	24.11
Total pallidum	DEP	9	16	1231	546	685	0.051 ± 0.028 (-0.004 to 0.106)	0.07	0.008	< 0.001*	67.88*
	DEP-Mix	5	5	494	252	242	0.044 ± 0.038 (-0.031 to 0.118)	0.25	0.003	0.18	38.94
Right pallidum	DEP	7	13	947	411	536	0.028 ± 0.020 (-0.012 to 0.068)	0.16	0.003	< 0.001*	64.66*
	DEP-Mix	3	3	223	117	106	0.054 ± 0.033 (-0.011 to 0.120)	0.10	0.000	0.98	0.00
Left pallidum	DEP	7	13	947	411	536	0.025 ± 0.015 (-0.004 to 0.054)	0.09	0.001	0.14	19.16
	DEP-Mix	3	3	223	117	106	0.018 ± 0.038 (-0.056 to 0.092)	0.63	0.001	0.24	25.99
Total thalamus	DEP	7	13	938	395	543	0.140 ± 0.194 (-0.242 to 0.520)	0.47	0.400	< 0.001*	87.36*
	DEP-Mix	3	3	214	101	113	0.774 ± 0.184 (0.414 to 1.134)	< 0.001*	0.000	0.75	0.00
Right thalamus	DEP	6	12	874	363	511	0.091 ± 0.097 (-0.100 to 0.281)	0.35	0.081	< 0.001*	76.54*
	DEP-Mix	6	12	874	363	511	0.036 ± 0.098 (-0.156 to 0.227)	0.72	0.076	< 0.001*	73.60*
Left thalamus	DEP	6	12	874	363	511	0.036 ± 0.098 (-0.156 to 0.227)	0.72	0.076	< 0.001*	73.60*
	DEP-Mix	4	9	563	226	337	-0.018 ± 0.025 (-0.067 to 0.032)	0.49	0.004	< 0.001*	69.57*

CI = confidence interval; Cur = current; DEP = depression; EO = early onset; FE = first episode; *f* = proportion real differences between studies; *k* = number of samples or subsamples; LO = late onset; ME = multiple episodes; Med = taking antidepressants; Mix = mixed group; noMed = not taking antidepressants; *Q*, *p* = *Q* statistic, *p* value; Rem = remission; SE = standard error; τ^2 = variance of true effects; TR = treatment-resistant. *Significance at $p \leq 0.05$ and $I^2 > 50\%$.

total putamen volume in participants with depression (Fig. 7A). We also found significant differences in 1 subgroup indicating that compared with healthy controls, participants with depression in mixed groups had 2.4% ($z = 2.742$, $p = 0.006$) lower total putamen volume. We found significant heterogeneity in the first analysis (Table 1 and Appendix 1, Fig. S17).

Nine studies reported right putamen volume differences ($n = 1248$, age 47.8 yr, 59.3% female).^{60,71,75,83,88,94,98-100} Significant differences represented 2.0% ($z = 1.995$, $p = 0.046$) lower right putamen volume in participants with depression (Table 1, Fig. 7C and Appendix 1, Fig. S19).

Thalamus

Seven studies reported total thalamus volume differences ($n = 938$, age 43.0 yr, 55.7% female).^{60,71,75,83,88,94,104} Significant differences represented 5.5% ($z = 4.216$, $p < 0.001$) lower total thalamus volume in participants with depression in mixed groups (Table 1 and Appendix 1, Fig. S35).

Intracranial volume

Forty-six studies reported intracranial volume differences ($n = 4245$, age 51.1 yr, 65.6 female).^{13,15,34,40,54-56,60,61,63,66,67,70,72,74,76,77,80,82,83,85,86,89-92,105-124} Significant differences represented 0.9% ($z = 2.009$, $p = 0.045$) lower intracranial volume in participants with depression in mixed groups (Table 1 and Appendix 1, Fig. S44).

Assessment of comorbid anxiety: analysis excluding anxiety disorders

We investigated 10 regions, given minimum requirements: 4 global and 6 subcortical structures. A summary of volumetric differences between healthy controls and participants with depression in each region is provided in Figure 2 (centre). Effects were $0.7\% \pm 1.3$ (mean \pm SD; range -1.3% to 4.5%) greater compared to the main analyses. We found significant differences in 6 of 10 regions investigated (Table 2 and Appendix 1, Table S5 for detailed demographics).

Grey matter volume

Eight studies reported grey matter volume differences ($n = 892$, age 42.0 yr, 55.5% female).^{17,34,35,38,40,41,43,44} Significant differences represented 1.6% ($z = 2.288$, $p = 0.023$) lower grey matter volume in participants with depression and no comorbid anxiety (Table 2 and Fig. 3B; Appendix 1, Fig. S4).

Hippocampus

Thirty studies reported total hippocampal volume differences ($n = 2888$, age 54.8 yr, 64.1% female).^{40,44,48,50-52,54,56-58,61,62,64,67,70-74,79,81,83-87,93,94,96,97} Significant differences represented 4.1% ($z = 4.247$, $p < 0.001$) lower total hippocampal volume in participants with depression and no comorbid anxiety. We also found significant differences in 2 subgroups indicating that, compared with healthy controls, participants with depression in mixed groups had 4.4% ($z = 3.400$, $p < 0.001$) lower total hippocampal volume and

participants with late-onset depression had 6.7% ($z = 3.764, p < 0.001$) lower total hippocampal volume. All significant results showed significant heterogeneity (Table 2 and Fig. 8; Appendix 1, Fig. S6).

Twenty-eight studies reported right and left hippocampal volume differences ($n = 2773$, age 54.8 yr, 64.6% female).^{40,44,50–52,54,56–58,61,62,64,70–74,79,81,83–87,93,94,96,97} Significant differences represented 4.4% ($z = 4.433, p < 0.001$) lower right and 4.2% ($z = 4.294, p < 0.001$) lower left hippocampal volume in participants with depression and no comorbid anxiety. We also found significant differences in 2 subgroups indicating that, compared with healthy controls, participants with depression in mixed groups had 4.4% ($z = 3.400, p < 0.001$) lower right and 4.8% ($z = 4.025, p < 0.001$) lower left hippocampal volumes and participants with late-onset depression had 6.6% ($z = 3.113, p = 0.002$) lower right and 6.2% ($z = 3.412, p < 0.001$) lower left hippocampal volumes. Except for participants with late-onset depression, all significant results showed significant heterogeneity (Table 2, Fig. 9, Fig. 10 and Appendix 1, Fig. S8 and S10).

Putamen

Six studies reported total, right and left putamen volume differences ($n = 607$, age 60.0 yr, 66.2% female).^{71,83,94,98–100} Significant differences represented 4.2% ($z = 2.704, p = 0.007$) lower total, 4.3% ($z = 3.137, p = 0.002$) lower right and 4.2% ($z = 2.247, p = 0.025$) lower left putamen volumes in participants with depression and no comorbid anxiety. Only the significant result in total putamen volume showed significant heterogeneity (Table 2; Fig. 7B, D and E; and Appendix 1, Fig. S18, S20 and S22).

Pallidum

Four studies reported right pallidum volume differences ($n = 306$, age 53.3 yr, 59.2% female).^{71,83,94,98} Significant differences

represented 3.2% ($z = 2.067, p = 0.039$) lower right pallidum volume in participants with depression and no comorbid anxiety (Table 2, Fig. 11A and Appendix 1, Fig. S32).

Thalamus

Three studies reported total, right and left thalamus volume differences ($n = 233$, age 58.3 yr, 63.5% female).^{71,83,94} Significant differences represented 3.1% ($z = 3.086, p = 0.002$) lower total, 3.3% ($z = 2.290, p = 0.022$) lower right and 3.1% ($z = 2.120, p = 0.034$) lower left thalamus volumes in participants with depression and no comorbid anxiety (Table 2; Fig. 11B, C and D; and Appendix 1, Fig. S36, S38 and S40).

Intracranial volume

Twenty-six studies reported intracranial volume differences ($n = 2741$, age 53.8 yr, 66.0% female).^{13,15,34,40,54,56,61,67,70,72,74,83,85,86,106,109–112,115,118–122,124} Significant differences represented 1.0% ($z = 2.225, p = 0.026$) lower intracranial volume in participants with depression and no comorbid anxiety (Table 2 and Appendix 1, Fig. S45).

Assessment of comorbid anxiety: analysis with comorbid anxiety disorders

We investigated 8 regions, given minimum requirements: 3 global and 5 subcortical structures. A summary of volumetric differences in each region is provided in Figure 2 (right). Effects were $2.7\% \pm 2.8$ (mean \pm SD; range -0.5% to 9.5%) lower compared with depression and no comorbid anxiety. We found significant differences only in the amygdala (Table 3 and Appendix 1, Table S5 for detailed demographics).

Amygdala

Four studies reported total and left amygdala volume differences ($n = 366$, age 36.2 yr, 55.2% female).^{60,68,91,125}




Fig. 3: Volumetric effect of depression in grey matter. Forest plots of (A) the main effect of depression and (B) the effect of depression excluding comorbid anxiety in grey matter. Positive values represent greater volume in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; GMV = grey matter volume; HC = healthy controls; MD = mean difference; RE = random effects.




Fig. 4: Volumetric effect of depression in total hippocampus. Forest plots of (A) the main effect of depression in total hippocampus, and of the effect of depression in total hippocampus for the following subgroups: (B) mixed group; (C) late-onset depression; and (D) multiple episodes of depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is milliliters. CI = confidence interval; DEP = participants with depression; HC = healthy controls; MD = mean difference; RE = random-effects; THcV = total hippocampus volume.




Fig. 5: Volumetric effect of depression in right hippocampus. Forest plots of (A) the main effect of depression in right hippocampus, and of the effect of depression in right hippocampus for the following subgroups: (B) mixed group; (C) early-onset depression; (D) late-onset depression; and (E) multiple episodes of depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is milliliters. CI = confidence interval; DEP = participants with depression; HC = healthy controls; MD = mean difference; RHcV = right hippocampus volume; RE = random effects.




Fig. 6: Volumetric effect of depression in left hippocampus. Forest plots of (A) the main effect of depression in left hippocampus, and of the effect of depression in left hippocampus for the following subgroups: (B) mixed group; (C) late-onset depression; and (D) multiple episodes of depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; LHcV = left hippocampus volume; MD = mean difference; RE: random effects.




Fig. 7: Volumetric effect of depression in putamen. Forest plots of (A) the main effect of depression in total putamen; (B) the effect of depression without comorbid anxiety in total putamen; (C) the main effect of depression in right putamen; (D) the effect of depression without comorbid anxiety in right putamen; and (E) the effect of depression without comorbid anxiety in left putamen. Positive values represent greater volume in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; LPuV = left putamen volume; MD = mean difference; RE = random effects; RPuV = right putamen volume; TPuV = total putamen volume.

Table 2: Meta-analyses per brain region in depression excluding comorbidity (part 1 of 2)

Region	n				Meta-analysis results						
	Analysis	Studies, n	k	Total	Control	Depression	Mean volume difference ± SE (95% CI), mL	p value	τ ²	Q p	I ² , %
Total brain	DEP	10	13	1190	472	718	-7.371 ± 6.963 (-21.017 to 6.276)	0.29	0.000	0.48	0.00
	DEP-Mix	4	4	509	202	307	1.279 ± 10.776 (-19.841 to 22.400)	0.91	0.000	0.86	0.00
	DEP-EO	3	3	205	104	101	9.827 ± 16.042 (-21.615 to 41.269)	0.54	0.000	0.64	0.00
	DEP-LO	3	3	191	104	87	7.435 ± 15.440 (-22.828 to 37.697)	0.63	0.000	0.46	0.00
Grey matter	DEP	8	10	892	387	505	11.005 ± 4.810 (1.578 to 20.432)	0.022*	22.880	0.55	9.86
	DEP-FE	3	3	178	98	80	15.396 ± 9.344 (-2.919 to 33.710)	0.10	0.000	0.44	0.00
White matter	DEP	7	8	779	320	459	3.662 ± 4.126 (-4.425 to 11.749)	0.37	0.000	0.49	0.00
	DEP	23	30	2353	1083	1270	13.802 ± 6.204 (1.642 to 25.962)	0.026*	191.157	0.27	17.78
Intracranial	DEP-Mix	16	16	1686	809	877	12.765 ± 7.932 (-2.782 to 28.312)	0.11	230.603	0.19	24.89
	DEP-EO	4	4	365	233	132	21.650 ± 15.926 (-9.564 to 52.864)	0.17	0.000	0.45	0.00
	DEP-FE	3	3	282	197	85	20.913 ± 16.023 (-10.491 to 52.317)	0.19	0.000	0.33	0.00
	DEP-noMed	3	3	134	82	52	-37.443 ± 23.304 (-83.119 to 8.233)	0.11	0.000	0.65	0.00
Total hippocampus	DEP	22	28	2121	952	1169	0.246 ± 0.058 (0.133 to 0.360)	< 0.001*	0.073	< 0.001*	83.74*
	DEP-Mix	16	17	1344	651	693	0.261 ± 0.077 (0.111 to 0.411)	< 0.001*	0.080	< 0.001*	85.31*
	DEP-EO	3	3	275	156	119	0.107 ± 0.109 (-0.107 to 0.321)	0.33	0.022	0.07	62.09*
	DEP-LO	5	5	409	223	186	0.373 ± 0.099 (0.179 to 0.567)	< 0.001*	0.032	0.027*	65.14*
DEP-Rem	DEP-Rem	6	6	441	280	161	0.065 ± 0.119 (-0.168 to 0.297)	0.58	0.064	< 0.001*	77.13*
	DEP-Rem	4	4	274	158	116	-0.020 ± 0.068 (-0.153 to 0.113)	0.77	0.000	0.61	0.00
	DEP	20	25	2006	903	1103	0.134 ± 0.030 (0.075 to 0.193)	< 0.001*	0.015	< 0.001*	69.53*
	DEP-Mix	14	15	1229	602	627	0.128 ± 0.037 (0.056 to 0.201)	< 0.001*	0.013	< 0.001*	67.88*
DEP-EO	DEP-EO	3	3	275	156	119	0.084 ± 0.050 (-0.015 to 0.183)	0.09	0.002	0.27	28.16
	DEP-LO	5	5	409	223	186	0.189 ± 0.061 (0.070 to 0.308)	0.002*	0.010	0.05	57.59*
	DEP-FE	6	6	441	280	161	0.032 ± 0.072 (-0.109 to 0.173)	0.65	0.021	0.007*	68.74*
	DEP-Rem	4	4	274	158	116	-0.007 ± 0.044 (-0.093 to 0.079)	0.88	0.000	0.65	0.00
Left hippocampus	DEP	20	25	2006	903	1103	0.124 ± 0.029 (0.067 to 0.180)	< 0.001*	0.013	< 0.001*	67.74*
	DEP-Mix	14	15	1229	602	627	0.137 ± 0.034 (0.070 to 0.204)	< 0.001*	0.010	0.001*	62.22*
	DEP-EO	3	3	275	156	119	0.036 ± 0.053 (-0.069 to 0.141)	0.50	0.003	0.18	39.69
	DEP-LO	5	5	409	223	186	0.167 ± 0.049 (0.071 to 0.264)	< 0.001*	0.005	0.17	38.87
DEP-FE	DEP-FE	6	6	441	280	161	0.041 ± 0.049 (-0.055 to 0.137)	0.41	0.005	0.17	34.46
	DEP-Rem	4	4	274	158	116	-0.002 ± 0.043 (-0.086 to 0.082)	0.96	0.000	0.53	0.00
	DEP	9	12	705	314	391	0.199 ± 0.109 (-0.014 to 0.412)	0.07	0.130	< 0.001*	93.25*
	DEP-Mix	4	4	257	128	129	0.040 ± 0.075 (-0.108 to 0.188)	0.60	0.015	0.039*	66.18*
DEP-LO	DEP-LO	3	3	177	91	86	-0.146 ± 0.182 (-0.503 to 0.211)	0.42	0.087	< 0.001*	89.00*
	DEP-Rem	3	3	127	70	57	0.061 ± 0.157 (-0.246 to 0.369)	0.70	0.056	0.012*	76.19*
	DEP	9	12	705	314	391	0.094 ± 0.052 (-0.009 to 0.195)	0.07	0.026	< 0.001*	84.76*
	DEP-Mix	4	4	257	128	129	0.022 ± 0.030 (-0.037 to 0.080)	0.46	0.000	0.27	0.02
DEP-FE	DEP-FE	3	3	177	91	86	-0.074 ± 0.087 (-0.244 to 0.096)	0.40	0.016	0.017*	73.80*
	DEP-Rem	3	3	127	70	57	-0.003 ± 0.079 (-0.158 to 0.152)	0.97	0.009	0.14	48.99

Table 2: Meta-analyses per brain region in depression excluding comorbidity (part 2 of 2)

Region	Analysis	Studies, <i>n</i>	<i>k</i>	<i>n</i>			Depression	Mean volume difference ± SE (95% CI), mL	<i>p</i> value	τ^2	<i>Q p</i>	<i>I²</i> , %
				Total	Control	Depression						
Left amygdala	DEP	9	12	705	314	391	0.105 ± 0.056 (-0.004 to 0.213)	0.06	0.031	< 0.001*	87.46*	
	DEP-Mix	4	4	257	128	129	0.028 ± 0.042 (-0.053 to 0.110)	0.50	0.003	0.12	49.46	
	DEP-FE	3	3	177	91	86	-0.064 ± 0.099 (-0.257 to 0.130)	0.52	0.024	0.001*	82.32*	
Total putamen	DEP-Rem	3	3	127	70	57	0.050 ± 0.083 (-0.113 to 0.212)	0.55	0.013	0.06	62.05*	
	DEP	6	6	607	268	339	0.335 ± 0.124 (0.092 to 0.578)	0.007*	0.053	0.029*	58.96*	
	DEP-Mix	4	4	435	180	255	0.148 ± 0.096 (-0.040 to 0.336)	0.12	0.000	0.42	0.00	
Right putamen	DEP	6	6	607	268	339	0.167 ± 0.053 (0.063 to 0.271)	0.002*	0.001	0.50	2.61	
	DEP-Mix	4	4	435	180	255	0.087 ± 0.070 (-0.049 to 0.223)	0.21	0.000	0.73	0.00	
	DEP	6	6	607	268	339	0.171 ± 0.076 (0.022 to 0.321)	0.025*	0.015	0.12	44.32	
Left putamen	DEP-Mix	4	4	435	180	255	0.059 ± 0.066 (-0.070 to 0.188)	0.37	0.000	0.61	0.00	
	DEP	6	6	600	249	351	0.118 ± 0.083 (-0.045 to 0.281)	0.16	0.015	0.13	36.44	
	DEP-Mix	4	4	428	161	267	0.121 ± 0.146 (-0.166 to 0.407)	0.41	0.052	0.048*	62.73*	
Total caudate	DEP	6	6	600	249	351	0.044 ± 0.042 (-0.039 to 0.126)	0.30	0.000	0.54	0.03	
	DEP-Mix	4	4	428	161	267	0.041 ± 0.063 (-0.083 to 0.164)	0.52	0.002	0.30	14.86	
	DEP	6	6	600	249	351	0.078 ± 0.047 (-0.015 to 0.170)	0.10	0.002	0.34	11.50	
Right caudate	DEP	6	6	600	249	351	0.091 ± 0.073 (-0.052 to 0.234)	0.21	0.009	0.15	41.19	
	DEP-Mix	4	4	428	161	267	0.079 ± 0.045 (-0.009 to 0.168)	0.08	0.002	0.28	29.36	
	DEP	4	4	306	161	145	0.050 ± 0.024 (0.003 to 0.097)	0.039*	0.000	0.91	0.00	
Total pallidum	DEP	4	4	306	161	145	0.028 ± 0.037 (-0.045 to 0.101)	0.45	0.002	0.15	44.08	
	DEP	4	4	306	161	145	0.433 ± 0.140 (0.158 to 0.708)	0.002*	0.000	0.63	0.00	
	DEP	3	3	233	113	120	0.220 ± 0.096 (0.032 to 0.408)	0.022*	0.000	0.80	0.00	
Right thalamus	DEP	3	3	233	113	120	0.217 ± 0.102 (0.016 to 0.418)	0.034*	0.000	0.78	0.00	
	DEP	3	3	233	113	120						
	DEP	3	3	233	113	120						

CI = confidence interval; DEP = depression; EO = early onset; FE = first episode; *k* = number of samples or subsamples; LO = late onset; Mix = mixed group; noMed = not taking antidepressants; *Q p* = *Q* statistic *p* value; Rem = remission; SE = standard error; τ^2 = variance of true effects.
*Significance at $p \leq 0.05$ and $I^2 > 50\%$.

Significant differences represented 1.9% ($z = -2.566, p = 0.010$) greater total and 3.6% ($z = -3.317, p < 0.001$) greater left amygdala volumes in participants with depression and comorbid anxiety (Table 3, Fig. 12 and Appendix 1, Fig. S12 and S16).

Single study influence

We found no widespread evidence of single study influence, except for 1 study on intracranial volume (Appendix 1, Table S8).

Bias assessment

We detected evidence of bias in nearly half of all analyses (49%) using Egger regression and the trim-and-fill method, although we observed poor agreement between methods. However, bias changed the significance of the results in only a few cases. Twelve analyses that had previously been identified as nonsignificant attained significance once bias was accounted for. One analysis that was previously identified as significant (in left putamen volume) became nonsignificant once bias was accounted for, but the direction of effect remained unchanged (Appendix 1, Table S9).

Meta-regressions

Neither age nor sex was found to account for a significant proportion of the observed variance in total brain volume and hippocampal volume, individually or as part of models. We found similar results for segmentation procedure, depressive symptoms and medication status in hippocampal volume. Only sex — as the difference in percent female — was found to account significantly for 22.36% ($Q p = 0.033$) of the variance in intracranial volume (mean $-1.020, 95\% CI -1.956$ to -0.085 mL, $z = -2.138, p = 0.033$). In this manner, a higher percentage of females among participants with depression influenced reductions in intracranial volume (Appendix 1, Table S10).

Discussion

To the best of our knowledge, this is the first comprehensive systematic review of brain differences in depression to specifically consider comorbid anxiety. We showed that depression is associated with more widespread brain differences than previously demonstrated⁴⁻⁶ and, critically, that careful consideration of comorbid anxiety has a substantial effect on the magnitude of these differences.

Main findings

The effects of depression were larger in subcortical structures and most prominent in the hippocampus and thalamus, where significant reductions ranged from 3% to 7%. However, when we investigated depression in the absence of comorbid anxiety, the magnitude of these effects increased by 1% and revealed differences not previously reported^{4-6,20} in the bilateral thalamus, bilateral putamen and right pallidum. Furthermore,




Fig. 8: Volumetric effect of depression in total hippocampus without comorbid anxiety. Forest plots of (A) the effect of depression without comorbid anxiety in total hippocampus, and of the effect of depression in total hippocampus for the following subgroups: (B) mixed group; and (C) late-onset depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; MD = mean difference; RE = random-effects; THcV = total hippocampus volume.

a key finding was the 3% reduction in volumetric differences attributable to depression in the presence of comorbid anxiety.

Subcortical structures

Hippocampal differences were consistent with previous reviews^{4-8,12,20} and provided further evidence of an effect of depression on this structure. In line with previous meta-regressions,^{4,5} neither age nor sex, symptom severity, medication status or segmentation procedure influenced the magni-

tude of the hippocampal effects. However, hippocampal atrophy is associated with normal aging,¹²⁶ and the lack of significant effects may reflect a narrow age cohort available for analysis, or the influence of other unknown variables as demonstrated by the high residual heterogeneity. Nevertheless, these findings have profound implications for an aging population. Normal aging is associated with hippocampal atrophy in late life of up to 1.1% per year,¹²⁶ with an increase to 2.5% per year in mild cognitive impairment.¹²⁷ In this




Fig. 9: Volumetric effect of depression in right hippocampus without comorbid anxiety. Forest plots of (A) the effect of depression without comorbid anxiety in right hippocampus, and of the effect of depression in right hippocampus for the following subgroups: (B) mixed group and (C) late-onset depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; MD = mean difference; RHcV = right hippocampus volume; RE = random effects.

manner, the effects linked to depression may be equated to up to 3 to 4 years of typical aging, and may have implications for neurocognitive disorders.

Differences in thalamus and basal ganglia structures, on the other hand, have been inconsistently reported in depression,^{4-6,10,20} and have only been shown in the context of total volumes.^{5,20} Our findings demonstrate that differences in bilateral thalamus, bilateral putamen and right pallidum are also detectable in depression, although with a lower level of confidence in left putamen. Notably, these findings may elu-

cidate some depression symptomatology. Commonly reported sleep and appetite disturbances may be associated with thalamic differences;^{11,128} differences in putamen and pallidum, and their association with the reward system, may explain apathy and anhedonia^{6,129,130} and may have implications for motor disturbances.¹²⁸

Higher volumes in the amygdala have been inconsistently reported in depression,^{4-6,19} and significant effects have been shown only when controlling for medication status.¹⁹ We identified both higher and lower amygdala volumes in




Fig. 10: Volumetric effect of depression in left hippocampus without comorbid anxiety. Forest plots of (A) the effect of depression without comorbid anxiety in left hippocampus, and of the effect of depression in left hippocampus for the following subgroups: (B) mixed group and (C) late-onset depression. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; LHcV = left hippocampus volume; MD = mean difference; RE: random effects.

depression, although our analyses demonstrate that this apparent inconsistency is explained by comorbidity. Higher amygdala volumes were identified only in the context of comorbid anxiety, consistent with anxiety-related amygdalar hyperactivity.¹³¹ However, we note that our results differed from previously reported lower amygdala volumes in a voxel-based morphometry review.²² Methodological differences between structural and whole-brain analysis approaches are likely to account for the discrepancy, but clinical features may also contribute, since the earlier review analyzed a more homogeneous sample with multiple episodes.

Grey matter volume and intracranial volume

This review was also the first report of lower grey matter volume and intracranial volume in depression,⁴⁻⁶ possibly because of the larger number of studies included. Although the magnitude of these effects was lower than that of subcortical structures, it is worth noting that a 2% difference in grey matter volume represents a greater absolute tissue loss than that observed in the hippocampus and amygdala combined.

Therefore, this effect reflects not only the reduction detected in these structures but also a more widespread, global effect that may underlie cognitive symptoms. In contrast, intracranial volume differences need further scrutiny. Meta-regression showed that part of this effect (22%) was attributable to sex: a greater proportion of females with depression explained lower volumes. Furthermore, a single study was found to have undue influence on effects, putting into question the reliability of the findings for intracranial volume.

Chronic symptoms, age and laterality

There is an ongoing debate about whether brain differences associated with depression are modulated by depression symptoms, or by other factors such as laterality. Subgroup analyses suggested greater effects in the context of depression with multiple episodes and with late-onset depression. Although only significant in the hippocampus, these effects were consistent with previous meta-analyses⁵⁻⁷ and highlight the effect of symptom chronicity and the conjoint influence of depression and aging. Laterality effects, on the other hand,




Fig. 11: Volumetric effect of depression in pallidum and thalamus without comorbid anxiety. Forest plots of (A) the effect of depression without comorbid anxiety in right pallidum, and of the effect of depression without comorbid anxiety in (B) total thalamus, (C) right thalamus and (D) left thalamus. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is milliliters. CI = confidence interval; DEP = participants with depression; HC = healthy controls; LTV = left thalamus volume; MD = mean difference; RE = random effects; RPaV = right pallidum volume; RTV = right thalamus volume; TTV = total thalamus volume.

Table 3: Meta-analyses per brain region in depression comorbid with anxiety

Region	Analysis	Studies, n	k	Total	Control	Depression	Meta-analysis results				
							n	Mean volume difference ± SE (95% CI), mL	p value	τ^2	Q, p
Total brain	DEP	4	6	458	214	244	-1.866 ± 10.281 (-22.015 to 18.284)	0.86	0.000	0.85	0.00
Grey matter	DEP	5	6	742	375	367	3.559 ± 3.513 (-3.327 to 10.445)	0.31	0.000	0.15	0.00
Intracranial	DEP	9	16	654	270	384	-4.747 ± 9.293 (-22.961 to 13.467)	0.61	411.763	0.040*	38.08
	DEP-Mix	5	5	325	167	158	4.848 ± 12.412 (-19.479 to 29.175)	0.70	206.245	0.18	25.43
Total hippocampus	DEP	10	21	1049	417	632	0.105 ± 0.081 (-0.054 to 0.264)	0.20	0.104	< 0.001*	90.13*
	DEP-Mix	4	4	228	113	115	0.302 ± 0.207 (-0.104 to 0.708)	0.15	0.154	< 0.001*	91.54*
Right hippocampus	DEP	9	20	1006	399	607	0.057 ± 0.043 (-0.027 to 0.140)	0.18	0.023	< 0.001*	81.49*
	DEP-Mix	4	4	228	113	115	0.173 ± 0.108 (-0.038 to 0.384)	0.11	0.037	< 0.001*	83.69*
Left hippocampus	DEP	9	20	1006	399	607	0.073 ± 0.044 (-0.013 to 0.159)	0.10	0.026	< 0.001*	83.45*
	DEP-Mix	4	4	228	113	115	0.111 ± 0.107 (-0.098 to 0.320)	0.30	0.037	< 0.001*	83.78*
Total amygdala	DEP	4	11	366	113	253	-0.066 ± 0.026 (-0.116 to -0.016)	0.010*	0.000	0.25	0.05
Right amygdala	DEP	4	11	366	113	253	-0.013 ± 0.018 (-0.047 to 0.022)	0.48	0.000	0.69	0.09
Left amygdala	DEP	4	11	366	113	253	-0.062 ± 0.019 (-0.099 to -0.025)	< 0.001*	0.000	0.61	0.00
Total putamen	DEP	4	11	836	341	495	0.100 ± 0.115 (-0.125 to 0.325)	0.38	0.075	0.002*	63.52*
Total caudate	DEP	4	11	836	341	495	-0.059 ± 0.089 (-0.233 to 0.115)	0.51	0.046	0.002*	62.56*
Total pallidum	DEP	4	11	836	341	495	0.039 ± 0.040 (-0.039 to 0.116)	0.33	0.013	< 0.001*	78.85*

CI = confidence interval; DEP = depression; I^2 = proportion real differences between studies; k = number of samples or subsamples; Mix = mixed group; Q, p = Q statistic p value; SE = standard error; τ^2 = variance of true effects. *Significance at $p \leq 0.05$ and $F > 50\%$.

were not uniform. Smaller volumes were found mostly in the right hemisphere, with differences as high as 2% in some structures. However, we found the opposite trend in caudate and amygdala; the role and relevance of laterality effects needs further scrutiny.

Neurobiology of volumetric effects

Although the pathophysiology of depression remains unclear,^{11,132} the effects reported may reflect pathological activation of specific biological pathways and their combined effects.¹³² Brain atrophy may arise from hyperactivity of the hypothalamic-pituitary-adrenal axis and the neurotoxic effects of chronically elevated glucocorticoid levels.¹³³ Hypothalamic-pituitary-adrenal hyperactivity directly affects immune response, particularly through heightened proinflammatory activity.^{11,132} Chronically elevated proinflammatory cytokine levels are associated with impaired synaptogenesis and excessive microglial activation,¹¹ and may disrupt the integrity of the blood-brain barrier.¹³⁴ These effects translate to a neurotoxic environment that leads to impaired neurogenesis, neuronal loss and, over time, loss of brain tissue.^{11,132,134} This pathological cascade would affect most brain regions, but is likely to be more prominent in the thalamus and hippocampus, given their sensitivity to glucocorticoids,¹³⁵ and even more for the hippocampus given its involvement in neurogenesis.

In contrast, increased amygdalar volumes may be linked to heightened synaptogenesis or dendritic tree expansion¹³⁴ due to hyperactivity in anxious states.¹³¹ Increased volume has been demonstrated in patients with posttraumatic stress disorder,¹³⁶ but, conflicting evidence has been reported.¹³⁷ The neurobiology of the conjoint effect of depression and anxiety remains unknown, and limited literature precludes further insight. Our findings suggest a distinct pattern of volumetric differences, but it remains unclear whether these differences predate the onset of comorbidity, whether there is an ordered sequence where one disorder precedes the other, or whether these differences are the result of treatment. People with depression and comorbidity have been shown to have poor response to therapy, more adverse effects and lower remission rates,¹⁸ which would likely increase the number of treatments compared with other people with depression.

Limitations

We report a comprehensive account of the effect of depression and comorbid anxiety in brain structure, but some limitations must be acknowledged. Limited data on symptom severity and medication status reduced the sample size in meta-regressions to less than half of the included studies. These limitations further extended to subgroup analyses, where effects could not be studied in all structures. Significant heterogeneity in hippocampal meta-regressions indicated that other variables not investigated here make significant contributions to observed differences. Finally, the cross-sectional nature of the analyses limited causal




Fig. 12: Volumetric effect of depression in amygdala with comorbid anxiety. Forest plots of (A) the effect of depression with comorbid anxiety in total amygdala and (B) left amygdala. Positive values represent greater volumes in healthy controls, and negative values represent greater volumes in participants with depression. Unit of measurement is millilitres. CI = confidence interval; DEP = participants with depression; HC = healthy controls; LAV = left amygdala volume; MD = mean difference; RE = random effects; TAV = total amygdala volume.

inference. Longitudinal reviews with long follow-up periods are needed to demonstrate unambiguously that depression causes brain atrophy.

Conclusion

The present findings demonstrate profound and consistent brain changes associated with depression modulated by the presence of comorbid anxiety, chronicity of symptoms and onset of illness. Comorbid anxiety masked the effect of depression and underestimated volume differences, emphasizing the need for future studies to consistently examine anxiety comorbidity as a means of better understanding the independent role of each disorder in brain structure. These findings further highlight the need for effective treatments to improve long-term mental health and prevent additive effects to neurocognitive disorders later in life. People with depression and without comorbid anxiety are at higher risk of neurocognitive insults; screening for anxiety symptoms may effectively target this population for early intervention.

Affiliations: From the Centre for Research on Ageing, Health and Wellbeing, The Australian National University, Canberra, ACT, Australia (Espinoza Oyarce, Alateeq, Cherbuin); and the College of Engineering and Computer Science, The Australian National University, Canberra, ACT, Australia (Shaw).

Funding: D. Espinoza Oyarce is funded by the Australian Government Research Training Program (AGRTP) Scholarship. The funder had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the review; and in the decision to submit the paper for publication.

Competing interests: None declared.

Contributors: D. Espinoza Oyarce and N. Cherbuin designed the study. All authors acquired and analyzed the data. D. Espinoza

Oyarce, M. Shaw and N. Cherbuin wrote the article, which all authors reviewed. All authors approved the final version to be published and can certify that no other individuals not listed as authors have made substantial contributions to the paper.

ORCID: Daniela A. Espinoza Oyarce (<https://orcid.org/0000-0002-0843-9195>). Marnie E. Shaw (<https://orcid.org/0000-0002-9834-6725>). Nicolas Cherbuin (<https://orcid.org/0000-0001-6481-0748>).

References

- Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 2013;382: 1575-86.
- World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017.
- Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. *BMC Med* 2011;9:90.
- Arnone D, McIntosh AM, Ebmeier KP, et al. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. *Eur Neuropsychopharmacol* 2012;22:1-16.
- Kempton MJ, Salvador Z, Munafo MR, et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. *Arch Gen Psychiatry* 2011;68:675-90.
- Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, et al. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Hum Brain Mapp* 2009; 30:3719-35.
- McKinnon MC, Yucel K, Nazarov A, et al. A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. *J Psychiatry Neurosci* 2009;34:41-54.
- Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. *Am J Psychiatry* 2004;161:1957-66.
- Malykhin NV, Coupland NJ. Hippocampal neuroplasticity in major depressive disorder. *Neuroscience* 2015;309:200-13.
- Dusi N, Barlati S, Vita A, et al. Brain structural effects of antidepressant treatment in major depression. *Curr Neuropharmacol* 2015;13:458-65.
- Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. *Nat Rev Dis Primers* 2016;2:16065.

12. Schmaal L, Veltman DJ, van Erp TG, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA major depressive disorder working group. *Mol Psychiatry* 2016;21:806-12.
13. Huang Y, Coupland NJ, Lebel R, et al. Structural changes in hippocampal subfields in major depressive disorder: a high-field magnetic resonance imaging study. *Biol Psychiatry* 2013;74:62-8.
14. Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 2000;20:9104-10.
15. Malykhin NV, Carter R, Seres P, et al. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. *J Psychiatry Neurosci* 2010;35:337-43.
16. Wang JW, David DJ, Monckton JE, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. *J Neurosci* 2008;28:1374-84.
17. van Tol M-J, van der Wee NJ, van den Heuvel OA, et al. Regional brain volume in depression and anxiety disorders. *Arch Gen Psychiatry* 2010;67:1002-11.
18. Ionescu DF, Niciu MJ, Mathews DC, et al. Neurobiology of anxious depression: a review. *Depress Anxiety* 2013;30:374-85.
19. Hamilton JP, Siemer M, Gotlib IH. Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. *Mol Psychiatry* 2008;13:993-1000.
20. Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. *Am J Geriatr Psychiatry* 2013;21:184-95.
21. Eker C, Gonul AS. Volumetric MRI studies of the hippocampus in major depressive disorder: meanings of inconsistency and directions for future research. *World J Biol Psychiatry* 2010;11:19-35.
22. Bora E, Fornito A, Pantelis C, et al. Gray matter abnormalities in major depressive disorder: a meta-analysis of voxel based morphometry studies. *J Affect Disord* 2012;138:9-18.
23. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151(4):264-9, w64.
24. Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions*. London: Cochrane Collaboration; 2011.
25. R Core Team. *R: A language and environment for statistical computing*. 3.3.1 ed. Vienna: R Foundation for Statistical Computing; 2016.
26. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010;36:1-48.
27. Borenstein M, Hedges LV, Higgins JPT, et al. *Introduction to meta-analysis*. West Sussex: John Wiley & Sons, Ltd; 2009.
28. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
29. Wells GA, Shea B, O'Connell D, et al. *The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses*. Ottawa, Canada: Ottawa Hospital Research Institute; 2014. Available: www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 2017 Aug.).
30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
31. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. *J Clin Epidemiol* 2001;54:1046-55.
32. Duval S, Tweedie RA. Nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. *J Am Stat Assoc* 2000;95:89-98.
33. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455-63.
34. Abe O, Yamasue H, Kasai K, et al. Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression. *Psychiatry Res* 2010;181:64-70.
35. Arnone D, McKie S, Elliott R, et al. State-dependent changes in hippocampal grey matter in depression. *Mol Psychiatry* 2013;18:1265-72.
36. Cardoner N, Soriano-Mas C, Pujol J, et al. Brain structural correlates of depressive comorbidity in obsessive-compulsive disorder. *Neuroimage* 2007;38:413-21.
37. Devantier TA, Norgaard BL, Poulsen MK, et al. White matter lesions, carotid and coronary atherosclerosis in late-onset depression and healthy controls. *Psychosomatics* 2016;57:369-77.
38. Frodl T, Meisenzahl E, Zetsche T, et al. Enlargement of the amygdala in patients with a first episode of major depression. *Biol Psychiatry* 2002;51:708-14.
39. Machino A, Kunisato Y, Matsumoto T, et al. Possible involvement of major depression in gray matter abnormalities in persistent symptoms of major depression: an exploratory magnetic resonance imaging voxel-based morphometry study. *J Affect Disord* 2014;168:229-35.
40. Maller JJ, Daskalakis ZJ, Thomson RH, et al. Hippocampal volumetrics in treatment-resistant depression and schizophrenia: the devil's in de-tail. *Hippocampus* 2012;22:9-16.
41. Soriano-Mas C, Hernandez-Ribas R, Pujol J, et al. Cross-sectional and longitudinal assessment of structural brain alterations in melancholic depression. *Biol Psychiatry* 2011;69:318-25.
42. Stratmann M, Konrad C, Kugel H, et al. Insular and hippocampal gray matter volume reductions in patients with major depressive disorder. *PLoS One* 2014;9:e102692.
43. Ueda I, Kakeda S, Watanabe K, et al. Relationship between G1287A of the NET gene polymorphisms and brain volume in major depressive disorder: a voxel-based MRI study. *PLoS One* 2016;11:e0150712.
44. Van Eijndhoven P, van Wingen G, van Oijen K, et al. Amygdala volume marks the acute state in the early course of depression. *Biol Psychiatry* 2009;65:812-8.
45. Ribeiz SRI, Duran F, Oliveira MC, et al. Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. *PLoS One* 2013;8:e80049.
46. Yang S, Cheng Y, Mo Y, et al. Childhood maltreatment is associated with gray matter volume abnormalities in patients with first-episode depression. *Psychiatry Res Neuroimaging* 2017;268:27-34.
47. Penttila J, Paillere-Martinot ML, Martinot JL, et al. Cortical folding in patients with bipolar disorder or unipolar depression. *J Psychiatry Neurosci* 2009;34:127-35.
48. Abdallah CG, Jackowski A, Sato JR, et al. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. *Eur Neuropsychopharmacol* 2015;25:1082-90.
49. Ahdidan J, Foldager L, Rosenberg R, et al. Hippocampal volume and serotonin transporter polymorphism in major depressive disorder. *Acta Neuropsychiatr* 2013;25:206-14.
50. Ashtari M, Greenwald BS, Kramer-Ginsberg E, et al. Hippocampal/amygdala volumes in geriatric depression. *Psychol Med* 1999;29:629-38.
51. Ballmaier M, Narr KL, Toga AW, et al. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression. *Am J Psychiatry* 2008;165:229-37.
52. Bearden CE, Thompson PM, Avedissian C, et al. Altered hippocampal morphology in unmedicated patients with major depressive illness. *ASN Neuro* 2009;1:pii: e00020.
53. Bergouignan L, Chupin M, Czechowska Y, et al. Can voxel based morphometry, manual segmentation and automated segmentation equally detect hippocampal volume differences in acute depression? *Neuroimage* 2009;45:29-37.
54. Cole J, Toga AW, Hojatkashani C, et al. Subregional hippocampal deformations in major depressive disorder. *J Affect Disord* 2010;126:272-7.
55. Cole J, Weinberger DR, Mattay VS, et al. No effect of 5HTTLPR or BDNF Val66Met polymorphism on hippocampal morphology in major depression. *Genes Brain Behav* 2011;10:756-64.
56. Eker C, Kitis O, Taneli F, et al. Correlation of serum BDNF levels with hippocampal volumes in first episode, medication-free depressed patients. *Eur Arch Psychiatry Clin Neurosci* 2010;260:527-33.
57. Frodl T, Carballedo A, Hughes MM, et al. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. *Transl Psychiatry* 2012;2:e88.
58. Frodl T, Meisenzahl EM, Zetsche T, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. *J Clin Psychiatry* 2004;65:492-9.
59. Furtado CP, Maller JJ, Fitzgerald PB. A magnetic resonance imaging study of the entorhinal cortex in treatment-resistant depression. *Psychiatry Res* 2008;163:133-42.
60. Gifuni AJ, Ding Y, Olie E, et al. Subcortical nuclei volumes in suicidal behavior: nucleus accumbens may modulate the lethality of acts. *Brain Imaging Behav* 2016;10:96-104.
61. Han KM, Won E, Sim Y, et al. Hippocampal subfield analysis in medication-naïve female patients with major depressive disorder. *J Affect Disord* 2016;194:21-9.

62. Han K-M, Choi S, Jung J, et al. Cortical thickness, cortical and subcortical volume, and white matter integrity in patients with their first episode of major depression. *J Affect Disord* 2014;155:42-8.
63. Hickie IB, Naismith SL, Ward PB, et al. Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. *J Affect Disord* 2007;98:137-42.
64. Hviid LB, Ravnkilde B, Ahdidan J, et al. Hippocampal visuospatial function and volume in remitted depressed patients: an 8-year follow-up study. *J Affect Disord* 2010;125:177-83.
65. Janssen J, Hulshoff Pol HE, de Leeuw FE, et al. Hippocampal volume and subcortical white matter lesions in late life depression: comparison of early and late onset depression. *J Neurol Neurosurg Psychiatry* 2007;78:638-40.
66. Janssen J, Hulshoff Pol HE, Lampe IK, et al. Hippocampal changes and white matter lesions in early-onset depression. *Biol Psychiatry* 2004;56:825-31.
67. Kanelopoulos D, Gunning FM, Morimoto SS, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. *Am J Geriatr Psychiatry* 2011;19:13-22.
68. Keller J, Shen L, Gomez RG, et al. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. *Am J Psychiatry* 2008;165:872-80.
69. Kronmuller KT, Schroder J, Kohler S, et al. Hippocampal volume in first episode and recurrent depression. *Psychiatry Res* 2009;174:62-6.
70. Lim HK, Hong SC, Jung WS, et al. Automated hippocampal subfields segmentation in late life depression. *J Affect Disord* 2012;143:253-6.
71. Lim HK, Jung WS, Ahn KJ, et al. Regional cortical thickness and subcortical volume changes are associated with cognitive impairments in the drug-naive patients with late-onset depression. *Neuropsychopharmacology* 2012;37:838-49.
72. Lloyd AJ, Ferrier IN, Barber R, et al. Hippocampal volume change in depression: late- and early-onset illness compared. *Br J Psychiatry* 2004;184:488-95.
73. Maller JJ, Daskalakis ZJ, Fitzgerald PB. Hippocampal volumetrics in depression: the importance of the posterior tail. *Hippocampus* 2007;17:1023-7.
74. Meisenzahl EM, Seifert D, Bottlender R, et al. Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. *Eur Arch Psychiatry Clin Neurosci* 2010;260:127-37.
75. Nugent AC, Davis RM, Zarate CA Jr, et al. Reduced thalamic volumes in major depressive disorder. *Psychiatry Res* 2013;213:179-85.
76. Ota M, Sato N, Hidese S, et al. Structural differences in hippocampal subfields among schizophrenia patients, major depressive disorder patients, and healthy subjects. *Psychiatry Res Neuroimaging* 2017;259:54-9.
77. Phillips JL, Batten LA, Tremblay P, et al. A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. *Int J Neuropsychopharmacol* 2015;18:pyv037.
78. Posener JA, Wang L, Price JL, et al. High-dimensional mapping of the hippocampus in depression. *Am J Psychiatry* 2003;160:83-9.
79. Rusch BD, Abercrombie HC, Oakes TR, et al. Hippocampal morphometry in depressed patients and control subjects: relations to anxiety symptoms. *Biol Psychiatry* 2001;50:960-4.
80. Savitz J, Drevets WC, Smith CM, et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. *Neuropsychopharmacology* 2015;40:463-71.
81. Sawyer K, Corsentino E, Sachs-Ericsson N, et al. Depression, hippocampal volume changes, and cognitive decline in a clinical sample of older depressed outpatients and non-depressed controls. *Aging Ment Health* 2012;16:753-62.
82. Saylam C, Ucerler H, Kitis O, et al. Reduced hippocampal volume in drug-free depressed patients. *Surg Radiol Anat* 2006;28:82-7.
83. Sexton CE, Allan CL, Le Masurier M, et al. Magnetic resonance imaging in late-life depression: multimodal examination of network disruption. *Arch Gen Psychiatry* 2012;69:680-9.
84. Sivakumar PT, Kalmady SV, Venkatasubramanian G, et al. Volumetric analysis of hippocampal sub-regions in late onset depression: a 3 tesla magnetic resonance imaging study. *Asian J Psychiatr* 2015;13:38-43.
85. Tae WS, Kim SS, Lee KU, et al. Hippocampal shape deformation in female patients with unremitting major depressive disorder. *AJNR Am J Neuroradiol* 2011;32:671-6.
86. Taylor WD, McQuoid DR, Payne ME, et al. Hippocampus atrophy and the longitudinal course of late-life depression. *Am J Geriatr Psychiatry* 2014;22:1504-12.
87. Taylor WD, Steffens DC, Payne ME, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. *Arch Gen Psychiatry* 2005;62:537-44.
88. Turner AD, Furey ML, Drevets WC, et al. Association between subcortical volumes and verbal memory in unmedicated depressed patients and healthy controls. *Neuropsychologia* 2012;50:2348-55.
89. Vythilingam M, Heim C, Newport J, et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. *Am J Psychiatry* 2002;159:2072-80.
90. Vythilingam M, Vermetten E, Anderson GM, et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. *Biol Psychiatry* 2004;56:101-12.
91. Weniger G, Lange C, Irle E. Abnormal size of the amygdala predicts impaired emotional memory in major depressive disorder. *J Affect Disord* 2006;94:219-29.
92. Wolkowitz OM, Mellon SH, Lindqvist D, et al. PBMC telomerase activity, but not leukocyte telomere length, correlates with hippocampal volume in major depression. *Psychiatry Res* 2015;232:58-64.
93. Zannas AS, McQuoid DR, Payne ME, et al. Negative life stress and longitudinal hippocampal volume changes in older adults with and without depression. *J Psychiatr Res* 2013;47:829-34.
94. Zhao K, Liu H, Yan R, et al. Altered patterns of association between cortical thickness and subcortical volume in patients with first episode major depressive disorder: a structural MRI study. *Psychiatry Res Neuroimaging* 2017;260:16-22.
95. Zhao K, Liu H, Yan R, et al. Cortical thickness and subcortical structure volume abnormalities in patients with major depression with and without anxious symptoms. *Brain Behav* 2017;7:e00754.
96. Eker MC, Kitis O, Okur H, et al. Smaller hippocampus volume is associated with short variant of 5-HTTLPR polymorphism in medication-free major depressive disorder patients. *Neuropsychobiology* 2011;63:22-8.
97. Frodl T, Jager M, Smajstrovla I, et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. *J Psychiatry Neurosci* 2008;33:423-30.
98. Lacerda ALT, Nicoletti MA, Brambilla P, et al. Anatomical MRI study of basal ganglia in major depressive disorder. *Psychiatry Res* 2003;124:129-40.
99. Lenze EJ, Sheline YI. Absence of striatal volume differences between depressed subjects with no comorbid medical illness and matched comparison subjects. *Am J Psychiatry* 1999;156:1989-91.
100. Pan CC, McQuoid DR, Taylor WD, et al. Association analysis of the COMT/MTHFR genes and geriatric depression: an MRI study of the putamen. *Int J Geriatr Psychiatry* 2009;24:847-55.
101. Savitz J, Dantzer R, Meier TB, et al. Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. *Psychoneuroendocrinology* 2015;62:54-8.
102. Dombrovski AY, Siegle GJ, Szanto K, et al. The temptation of suicide: striatal gray matter, discounting of delayed rewards, and suicide attempts in late-life depression. *Psychol Med* 2012;42:1203-15.
103. Sacchet MD, Camacho MC, Livermore EE, et al. Accelerated aging of the putamen in patients with major depressive disorder. *J Psychiatry Neurosci* 2017;42:164-71.
104. Parashos IA, Tupler LA, Blitchington T, et al. Magnetic-resonance morphometry in patients with major depression. *Psychiatry Res* 1998;84:7-15.
105. Bijanki KR, Hodis B, Brumm MC, et al. Hippocampal and left subcallosal anterior cingulate atrophy in psychotic depression. *PLoS One* 2014;9:e110770.
106. Caetano SC, Hatch JP, Brambilla P, et al. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. *Psychiatry Res* 2004;132:141-7.
107. Carceller-Sindreu M, de Diego-Adelino J, Serra-Blasco M, et al. Volumetric MRI study of the habenula in first episode, recurrent and chronic major depression. *Eur Neuropsychopharmacol* 2015;25:2015-21.

108. Colloby SJ, Vasudev A, O'Brien JT, et al. Relationship of orthostatic blood pressure to white matter hyperintensities and subcortical volumes in late-life depression. *Br J Psychiatry* 2011;199:404-10.
109. De Winter FL, Emsell L, Bouckaert F, et al. No association of lower hippocampal volume with Alzheimer's disease pathology in late-life depression. *Am J Psychiatry* 2017;174:237-45.
110. Elderkin-Thompson V, Ballmaier M, Helleman G, et al. Daily functioning and prefrontal brain morphology in healthy and depressed community-dwelling elderly. *Am J Geriatr Psychiatry* 2008;16:633-42.
111. Emsell L, Adamson C, De Winter FL, et al. Corpus callosum macro and microstructure in late-life depression. *J Affect Disord* 2017;222:63-70.
112. Han KM, Kim D, Sim Y, et al. Alterations in the brainstem volume of patients with major depressive disorder and their relationship with antidepressant treatment. *J Affect Disord* 2017;208:68-75.
113. Klausner P, Fornito A, Lorenzetti V, et al. Cortico-limbic network abnormalities in individuals with current and past major depressive disorder. *J Affect Disord* 2015;173:45-52.
114. Kumar A, Jin Z, Bilker W, et al. Late-onset minor and major depression: early evidence for common neuroanatomical substrates detected by using MRI. *Proc Natl Acad Sci U S A* 1998;95:7654-8.
115. Lavretsky H, Ballmaier M, Pham D, et al. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. *Am J Geriatr Psychiatry* 2007;15:386-94.
116. Lavretsky H, Roybal DJ, Ballmaier M, et al. Antidepressant exposure may protect against decrement in frontal gray matter volumes in geriatric depression. *J Clin Psychiatry* 2005;66:964-7.
117. Rodriguez-Cano E, Sarro S, Monte GC, et al. Evidence for structural and functional abnormality in the subgenual anterior cingulate cortex in major depressive disorder. *Psychol Med* 2014;44:3263-73.
118. Taylor WD, Boyd B, McQuoid DR, et al. Widespread white matter but focal gray matter alterations in depressed individuals with thoughts of death. *Prog Neuropsychopharmacol Biol Psychiatry* 2015;62:22-8.
119. Taylor WD, Macfall JR, Payne ME, et al. Orbitofrontal cortex volume in late life depression: influence of hyperintense lesions and genetic polymorphisms. *Psychol Med* 2007;37:1763-73.
120. Vasic N, Wolf ND, Gron G, et al. Baseline brain perfusion and brain structure in patients with major depression: a multimodal magnetic resonance imaging study. *J Psychiatry Neurosci* 2015;40:412-21.
121. Vassilopoulou K, Papathanasiou M, Michopoulos I, et al. A magnetic resonance imaging study of hippocampal, amygdala and subgenual prefrontal cortex volumes in major depression subtypes: melancholic versus psychotic depression. *J Affect Disord* 2013;146:197-204.
122. Weber K, Giannakopoulos P, Delaloye C, et al. Volumetric MRI changes, cognition and personality traits in old age depression. *J Affect Disord* 2010;124:275-82.
123. Wisse LE, Biessels GJ, Stegenga BT, et al. Major depressive episodes over the course of 7 years and hippocampal subfield volumes at 7 tesla MRI: the PRÉDICT-MR study. *J Affect Disord* 2015;175:1-7.
124. Fung G, Deng Y, Zhao Q, et al. Distinguishing bipolar and major depressive disorders by brain structural morphometry: a pilot study. *BMC Psychiatry* 2015;15:298.
125. Lorenzetti V, Allen NB, Whittle S, et al. Amygdala volumes in a sample of current depressed and remitted depressed patients and healthy controls. *J Affect Disord* 2010;120:112-9.
126. Fraser MA, Shaw ME, Cherbuin N. A systematic review and meta-analysis of longitudinal hippocampal atrophy in healthy human ageing. *Neuroimage* 2015;112:364-74.
127. Tabatabaei-Jafari H, Shaw ME, Cherbuin N. Cerebral atrophy in mild cognitive impairment: a systematic review with meta-analysis. *Alzheimers Dement (Amst)* 2015;1:487-504.
128. Herrero MT, Barcia C, Navarro JM. Functional anatomy of thalamus and basal ganglia. *Childs Nerv Syst* 2002;18:386-404.
129. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. *Curr Opin Neurobiol* 2001;11:240-9.
130. Knowland D, Lim BK. Circuit-based frameworks of depressive behaviors: the role of reward circuitry and beyond. *Pharmacol Biochem Behav* 2018;174:42-52.
131. Grupe DW, Nitschke JB. Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective. *Nat Rev Neurosci* 2013;14:488-501.
132. Dean J, Keshavan M. The neurobiology of depression: an integrated view. *Asian J Psychiatry* 2017;27:101-11.
133. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. *J Neurosci* 1985;5:1222-7.
134. Sild M, Ruthazer ES, Booij L. Major depressive disorder and anxiety disorders from the glial perspective: etiological mechanisms, intervention and monitoring. *Neurosci Biobehav Rev* 2017;83:474-88.
135. Berardelli R, Karamouzis I, D'Angelo V, et al. Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans. *Endocrine* 2013;43:51-8.
136. Moyer A. Post-traumatic stress disorder and magnetic resonance imaging. *Radiol Technol* 2016;87:649-67.
137. O'Doherty DC, Chitty KM, Saddiqui S, et al. A systematic review and meta-analysis of magnetic resonance imaging measurement of structural volumes in posttraumatic stress disorder. *Psychiatry Res* 2015;232:1-33.